Compare Figs Inc (FIGS) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Illumina, Inc. — how do they compare? Figs Inc trades at $15.19 (market cap $2.49B), while Illumina, Inc. trades at $267.69 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 16× Figs Inc's market cap, and Figs Inc is more actively traded (5,964,311 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Illumina, Inc. for 83 Days on average.
| FIGS | ILMN | |
|---|---|---|
Market Cap | $2.49B | $39.95B |
Volume | 5,964,311 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $293.69 |
52-Week Low | $6.90 | $91.00 |
Typical Hold Time | 33 Days | 83 Days |
Enterprise Value | $2.25B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.06, down 0.28% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2025 revenue reaching $631.10M and net income of $34.25M, representing a 5.42% margin. Recent earnings beats and raised 2026 guidance indicate positive momentum, though valuation ratios remain elevated with a P/E of 45.39 and P/S of 4.02.
Wall Street maintains a bullish stance with 60% buy ratings and a $18.00 consensus price target, suggesting 28% upside potential. Key risks include execution challenges in international expansion and rich valuation multiples that require continued strong performance. The company's expanding customer base and international growth provide catalysts for future appreciation.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
